About

Acthera Therapeutics is a Swiss biotech startup, developing a unique and innovative type of mechano-responsive hard-shelled liposomes (HSL), for the targeted and controlled delivery of drugs. HSL are based on a patented synthetic lipid and release their payload when submitted to pathologically high shear stress. This enables the local delivery of an active thrombolytic drug at the site of an acute thrombotic obstruction leading to an acute cardiovascular event, such as acute myocardial infarction (AMI) or acute ischemic stroke (AIS). The local delivery will increase both the efficacy and safety if the pharmacological reperfusion therapy, and solve the current undertreatment, low efficacy and high risk associated with the currently available drugs. Our HSL-based thrombolytic agent is designed to meet the medical need of millions of patients who are currently dying or left with disability due to an acute cardiovascular event.